Apeloa Pharmaceutical Co.,Ltd (SHE:000739)
China
· Delayed Price · Currency is CNY 18.81
+0.02 (0.11%)
Apr 28, 2026, 3:05 PM CST
SHE:000739 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 9,445 | 9,728 | 11,957 | 11,440 | 10,506 | 8,910 | Upgrade
|
| Other Revenue | 55.48 | 55.48 | 65.35 | 33.92 | 39.1 | 32.44 | Upgrade
|
| Revenue | 9,501 | 9,784 | 12,022 | 11,474 | 10,545 | 8,943 | Upgrade
|
| Revenue Growth (YoY) | -17.77% | -18.62% | 4.77% | 8.81% | 17.92% | 13.49% | Upgrade
|
| Cost of Revenue | 6,953 | 7,298 | 9,225 | 8,621 | 8,075 | 6,579 | Upgrade
|
| Gross Profit | 2,548 | 2,486 | 2,796 | 2,853 | 2,470 | 2,364 | Upgrade
|
| Selling, General & Admin | 947.05 | 971.42 | 1,121 | 1,125 | 985.33 | 906.43 | Upgrade
|
| Research & Development | 576.41 | 611.17 | 641.47 | 624.87 | 532.92 | 446.22 | Upgrade
|
| Other Operating Expenses | 66.4 | 35.38 | 12.76 | 23.3 | 31.76 | 33.05 | Upgrade
|
| Operating Expenses | 1,601 | 1,608 | 1,785 | 1,775 | 1,563 | 1,405 | Upgrade
|
| Operating Income | 946.53 | 877.83 | 1,012 | 1,078 | 906.8 | 959.39 | Upgrade
|
| Interest Expense | -27.92 | -24.65 | -32.2 | -43.77 | -59.23 | -35.72 | Upgrade
|
| Interest & Investment Income | 90.25 | 131.78 | 92.17 | 113.47 | 75.83 | 165.7 | Upgrade
|
| Currency Exchange Gain (Loss) | -25.51 | -25.51 | 58.38 | 38.13 | 93.42 | -23.09 | Upgrade
|
| Other Non Operating Income (Expenses) | -34.61 | -1.82 | 2.18 | -23.85 | -5.38 | -3.58 | Upgrade
|
| EBT Excluding Unusual Items | 948.74 | 957.62 | 1,132 | 1,162 | 1,011 | 1,063 | Upgrade
|
| Gain (Loss) on Sale of Investments | -1.88 | - | -10.13 | -21.7 | -82.61 | -23.62 | Upgrade
|
| Gain (Loss) on Sale of Assets | 8.84 | 9.03 | 0.28 | 1.33 | 1.37 | 0.28 | Upgrade
|
| Asset Writedown | -0.19 | -5 | -8.37 | - | -4.67 | -7.95 | Upgrade
|
| Other Unusual Items | 111.03 | 104.55 | 89.22 | 63.23 | 86.52 | 82.67 | Upgrade
|
| Pretax Income | 1,067 | 1,066 | 1,203 | 1,205 | 1,012 | 1,114 | Upgrade
|
| Income Tax Expense | 175.16 | 175.52 | 172.44 | 149.34 | 22.89 | 158.53 | Upgrade
|
| Earnings From Continuing Operations | 891.38 | 890.68 | 1,031 | 1,055 | 989.17 | 955.55 | Upgrade
|
| Minority Interest in Earnings | -0.23 | -0 | 0.27 | 0.03 | 0 | - | Upgrade
|
| Net Income | 891.15 | 890.68 | 1,031 | 1,055 | 989.17 | 955.55 | Upgrade
|
| Net Income to Common | 891.15 | 890.68 | 1,031 | 1,055 | 989.17 | 955.55 | Upgrade
|
| Net Income Growth | -13.98% | -13.62% | -2.30% | 6.69% | 3.52% | 17.00% | Upgrade
|
| Shares Outstanding (Basic) | 1,150 | 1,153 | 1,163 | 1,169 | 1,174 | 1,179 | Upgrade
|
| Shares Outstanding (Diluted) | 1,150 | 1,153 | 1,163 | 1,169 | 1,174 | 1,179 | Upgrade
|
| Shares Change (YoY) | -1.11% | -0.86% | -0.52% | -0.40% | -0.38% | -0.00% | Upgrade
|
| EPS (Basic) | 0.77 | 0.77 | 0.89 | 0.90 | 0.84 | 0.81 | Upgrade
|
| EPS (Diluted) | 0.77 | 0.77 | 0.89 | 0.90 | 0.84 | 0.81 | Upgrade
|
| EPS Growth | -13.01% | -12.87% | -1.78% | 7.12% | 3.91% | 17.00% | Upgrade
|
| Free Cash Flow | 990.34 | 833.99 | 748.01 | 400.9 | 817 | -90.18 | Upgrade
|
| Free Cash Flow Per Share | 0.86 | 0.72 | 0.64 | 0.34 | 0.70 | -0.08 | Upgrade
|
| Dividend Per Share | 0.586 | 0.586 | 0.356 | 0.317 | 0.297 | 0.285 | Upgrade
|
| Dividend Growth | 64.68% | 64.68% | 12.35% | 6.70% | 4.21% | 17.28% | Upgrade
|
| Gross Margin | 26.81% | 25.41% | 23.26% | 24.86% | 23.42% | 26.43% | Upgrade
|
| Operating Margin | 9.96% | 8.97% | 8.42% | 9.39% | 8.60% | 10.73% | Upgrade
|
| Profit Margin | 9.38% | 9.10% | 8.58% | 9.20% | 9.38% | 10.69% | Upgrade
|
| Free Cash Flow Margin | 10.42% | 8.52% | 6.22% | 3.49% | 7.75% | -1.01% | Upgrade
|
| EBITDA | 1,633 | 1,540 | 1,576 | 1,631 | 1,296 | 1,318 | Upgrade
|
| EBITDA Margin | 17.19% | 15.74% | 13.11% | 14.21% | 12.29% | 14.74% | Upgrade
|
| D&A For EBITDA | 686.68 | 662.17 | 564.15 | 553.06 | 389.43 | 358.64 | Upgrade
|
| EBIT | 946.53 | 877.83 | 1,012 | 1,078 | 906.8 | 959.39 | Upgrade
|
| EBIT Margin | 9.96% | 8.97% | 8.42% | 9.39% | 8.60% | 10.73% | Upgrade
|
| Effective Tax Rate | 16.42% | 16.46% | 14.33% | 12.40% | 2.26% | 14.23% | Upgrade
|
| Revenue as Reported | 9,501 | 9,784 | 12,022 | 11,474 | 10,545 | 8,943 | Upgrade
|
| Advertising Expenses | - | 9.35 | 11.29 | 9.67 | 1.61 | 1.86 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.